TY - CHAP
T1 - Impact of genetic markers on treatment of non-small cell lung cancer
AU - Lamparella, Nicholas
AU - Barochia, Amit
AU - Almokadem, Salah
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2013
Y1 - 2013
N2 - Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.
AB - Non-small cell lung cancer represents a group of heterogeneous diseases. The last decade witnessed significant progress in improving our understanding of the biology of non-small cell lung cancer, which led to the identification of several genetic targets. Those genetic targets were utilized to explain clinical phenomena, such as the occurrence of non-small cell lung cancer in never-smokers, to predict response to conventional chemotherapy and biological agents, and to explain and predict resistance to therapy. The progress in the treatment of non-small cell lung cancer in the last few years was based on a new generation of population-enriched clinical trials that utilized genetic targets such as somatic EGFR mutations and ALK-EML4 mutations. In this review we will discuss the available information about the key genetic markers of non-small cell lung cancer and the pivotal clinical trials that validate the use of those genetic markers in non-small cell lung cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84873591227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873591227&partnerID=8YFLogxK
U2 - 10.1007/978-1-4614-6176-0_6
DO - 10.1007/978-1-4614-6176-0_6
M3 - Chapter
C2 - 23288638
AN - SCOPUS:84873591227
SN - 9781461461753
T3 - Advances in Experimental Medicine and Biology
SP - 145
EP - 164
BT - Impact of Genetic Targets on Cancer Therapy
PB - Springer Science and Business Media, LLC
ER -